Microdose drug test aims to find best cancer fighters
NCT ID NCT06366451
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested very small amounts of several cancer drugs (rilvegostomig, volrustomig, sabestomig, AZD9592, and pembrolizumab) injected directly into head and neck tumors in 17 people. The goal was to see how each drug affects the tumor's environment at the injection site. This approach helps researchers compare drugs quickly without exposing patients to full doses, but it cannot determine if the drugs actually treat the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rilvegostomig, volrustomig, sabestomig, AZD9592, and pembrolizumab (Keytruda)
What this could lead to
If successful, this study could help identify which drugs are most promising for treating head and neck cancer, guiding future larger trials.
What could go wrong
This is a very early (Phase 0) study with only 17 people, so it cannot prove any drug works. It only looks at immediate effects in the tumor, not long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical University of South Carolina
Charleston, South Carolina, 29407, United States
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
-
Oregon Health & Science University (OHSU)
Portland, Oregon, 97239, United States
-
Sarah Cannon Medical Center
Charleston, South Carolina, 29406, United States
-
UC Davis
Sacramento, California, 95817, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19107, United States